Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $175M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| 16.06.2021 | 5AM Ventur... | 5amventure... |
| - | a16z | a16z.com/ |
| - | Flucas Ven... | flucasvc.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 20.07.2022 | Series B | $100M | 5AM Ventur... |
| 16.06.2021 | - | $45M | - |
| 01.06.2018 | Series A | $30M | - |
Mentions in press and media 20
| Date | Title | Description |
| 03.03.2025 | The Most-Active, Spendiest Startup Investors Are Lagging Greatly In Lucrative Exits | 6 Shares Email Facebook Twitter LinkedIn The most-active, highest-spending startup investors are leading a lot of large new rounds lately. When it comes to exits, however, things look much, much slower. To illustrate, we used Crunchbase dat... |
| 21.07.2022 | CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic | – Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4’s regRNA Actuating Platform™, Harnessing the Power of Regulatory... |
| 21.07.2022 | CAMP4 Secures $100M Series B | CAMBRIDGE, MA, CAMP4 Therapeutics, a biotechnology company, announced the closing of a $100 million Series B round. >> Click here for more funding data on CAMP4 >> To export CAMP4 funding data to PDF and Excel, click here ... |
| 20.07.2022 | Camp4 Raises $100M in Series B Financing | CAMP4 Therapeutics, a Cambridge, MA-based biotechnology company harnessing the power of RNA to restore healthy protein expression, closed a $100m Series B funding round. The round was led by Enavate Sciences, a portfolio company created by ... |
| 20.07.2022 | Equipped with fresh $100M, CAMP4 heads up trail to the clinic, hoping partners will soon tag along | CAMP4 Therapeutics is bound for the clinical wilderness saddled with an additional $100 million, sealing a series B aimed at expanding the company’s platform and taking a lead asset into phase 1 trials. For now, the company is backpacking s... |
| 20.07.2022 | Lightspeed formed a re-investment team to help the VC prepare for a downturn | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Cheer someone on from the sidelines for long enough, and you might just get too attached. “Everyo... |
| 20.07.2022 | CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic | - |
| 22.04.2022 | It’s crunch time for CFOs when it comes to ESG reporting | This is the web version of CFO Daily, a newsletter on the trends and individuals shaping corporate finance. Sign up to get it delivered free to your inbox. Good morning, CFOs need to get serious about ESG—environmental, social, and corporat... |
| 20.04.2022 | Offering high salaries to attract top talent? If a recession occurs, that may backfire | This is the web version of CFO Daily, a newsletter on the trends and individuals shaping corporate finance. Sign up to get it delivered free to your inbox. Good morning, There’s been increased talk on Wall Street about a potential recession... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
Show more